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Direct antiGBM antibody induced alterations in glomerular
permselectivity
NEIL W. BOYCE and STEPHEN R. HOLDSWORTH
Department of Medicine, Prince Henry's Hospital, Melbourne, Australia
Direct antiGBM antibody induced alterations in gloinerular permselec-
tivity. The glomerular fixation of anti-glomerular—basement--membrane
(antiGBM) antibody is associated with complement activation, neutro-
phil accumulation, and renal injury. This injury manifests both as an
increase in the rate of urinary protein excretion and altered renal
hemodynamic characteristics. We have utilized an isolated perfused
kidney system (IPK) to assess the capacity of antiGBM antibody to
alter glomerular permselectivity in the absence of both glomerular
complement activation and neutrophil infiltration. Control perfusions
with Krebs—Henseleit buffered 5% albumin solutions containing normal
sheep globulin had a protein excretion rate of 0.223 0.044 mg/mm
(mean sEM). Assessment of glomerular perniselectivity using frac-
tional dextran clearances demonstrated an intact negative charge bar-
rier in control preparations. AntiGBM antibody bound in a dose related
fashion to the kidney and was localized to the glomerular basement
membrane on immunofluorescence. Antibody induced a significant
increase in mean protein excretion (2.009 0.681 mg/mm, P < 0.01) in
association with a loss of the glomerular filter's negative charge barrier.
These IPK studies demonstrate that antiGBM antibody can itself
produce proteinuria, in association with loss of the glomerular capillary
negative charge barrier, in the absence of all circulating humoral and
cellular inflammatory mediator systems.
AntiGBM antibody induced glomerulonephritis (GN) is wide-
ly used as a model of immune renal injury [1—3]. AntiGBM
antibody binding to the GBM is associated with complement
fixation and an influx of inflammatory cells, which are initially
polymorphonuclear leucocytes (PMN's) and later macrophages
[4—6]. This series of events is associated with damage to the
GBM, with a subsequent increased protein excretion and he-
modynamic abnormality [5, 71.
Many studies have shown that inflammatory cells are capable
of producing renal injury. Abrogation of PMN or macrophage
infiltration of the glomerulus in antiGBM GN by complement
and/or inflammatory cell depletion attenuates renal injury
[8—11]. In human glomerulonephritis however, inflammatory
cells are frequently absent from the damaged glomerular tuft,
despite the deposition of immunoglobulin and/or complement
[12—14]. This observation has stimulated a search for experi-
mental models of cell independent immune renal injury [15].
Potential mechanisms of inflammatory cell independent glomer-
ular injury include the activation of humoral inflammatory
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mediators (such as complement) and a direct effect of antibody
itself. Some experimental studies suggest that antibody may
induce injury without clear—cut evidence of PMN or comple-
ment involvement. Avian and occasional mammalian antiGBM
antibodies produce proteinuria in both rats and rabbits without
significant complement fixation or cellular infiltration [8, 15—16].
In the guinea pig, injury has been observed despite both
complement and neutrophil depletion [17—201. In vivo studies
usually investigate the role of any proposed inflammatory
mediator by assessing the effects of mediator depletion on a
particular model of experimental glomerulonephritis. However,
no matter how stringent the controls, depletion experiments are
always subject to the criticism that other known or unknown
modulators of injury may also be affected by the manipulations
used to induce depletion. The conclusions drawn from all
depletional studies are inferential.
The specific repletion of a putative mediator allows direct
evaluation of its role in acute antiGBM glomerulonephritis.
However, the sequential repletion of the proposed inflamma-
tory mediators (that is, antibody, complement, and neutrophils)
is not feasible in vivo. For these reasons, we have used an
isolated perfused rat kidney to allow assessment of the effects
on renal function of antiGBM antibody in the absence of
circulating soluble inflammatory mediators and inflammatory
cells. The IPK has recently been shown to be a suitable system
with which to study glomerular permselectivity [21]. A prelim-
inary communication by Couser et al [221 had suggested that
antibody administration produced an increase in protein excre-
tion in such a system. Recent studies have demonstrated the
importance of an intact GBM negative charge barrier in the
maintenance of normal glomerular perselectivity characteris-
tics, and the loss of this charge barrier in a variety of pathologic
states [23—271. We sought to quantitatively assess the effects of
antiGBM antibody binding on the protein excretion rate of the
IPK and to assess the functional effects of antiGBM antibody
on glomerular perrnselectivity in this circulating—cell free sys-
tern.
Methods
Perfusion technique
The perfusion apparatus used in these experiments was
similar to that described by Bowman and Maack [281 and
modified by Nakane et al [29] and Epstein et al [301. The
apparatus consisted of a central glass reservoir containing the
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perfusate which was recirculated by a roller peristaltic pump
(Watson—Marlow, London, UK). The perfusate traversed two
bubble traps and two 8 t filters (Millipore, Bedford, Massachu-
setts, USA) before being gassed with a mixture of 95% 02/5%
CO2 and delivered to the glass arterial perfusion cannula (P.A.
Brooks, Ducklington, UK).
Male Sprague—Dawley (SD) rats (300 to 450 g) were anesthe-
tized with an intraperitoneal injection of pentobarbital (40
mg/kg). A laparotomy was performed after injection of 1 ml of
10% mannitol and 500 IU sodium heparin (Commonwealth
Serum Laboratories, Melbourne, Australia) into the left femoral
vein. The right ureter was cannulated with polyethylene tubing
(PE1O, Intramedic, Parsippany, New Jersey, USA). The right
renal artery was cannulated via the superior mesenteric artery
and the kidney perfused during en-bloc dissection. After re-
moval, the kidney surface was rinsed with phosphate buffered
saline (PBS) and 20 to 40 ml of perfusate flushed through the
renal vasculature before transferring the kidney to a support
above the central reservoir. The renal vein was not cannulated.
The kidney was allowed to equilibrate for 10 minutes In all
experiments the perfusate flow rate was >20 mllmin at a
cannula tip pressure <120 mm Hg by the end of this equilibra-
tion period. The kidney was covered with a paraffin film
(Nescofilm, Bando Chemical md. Ltd., Kobe, Japan) and
perfused for periods up to 150 minutes. Samples of perfusate
were taken at 10 minute intervals and urine was collected over
20 minute intervals. All samples were stored at —20°C prior to
assay. Globulin fractions were added to the perfusate reservoir
at the end of the equilibration period (that is, t0).
The IPK perfusate consisted of a buffered albumin solution
(BAS); Krebs—Henseleit buffer containing 5.0 g/liter bovine
serum albumin (Sigma Chemical, St. Louis, Missouri, USA)
with added creatinine (10 to 20 mg/liter), glucose (5 mM/liter)
and amino acids [30]. It was prefiltered and then passed through
a 0.22 filter (Millipore, Bedford, Massachusetts, USA) before
use within eight hours of preparation. The perfusate total
hemolytic complement activity (CH50) was assessed using pre-
viously described techniques [31], and at all times there was no
demonstrable complement activity (CH50 = 0 units). Cell
counts performed on perfusate sampled from the perfusate
reservoir were at all times 0.0 cells/ml.
Assessment of renal function
Protein excretion. This was measured in duplicate samples by
the Coomassie Brilliant Blue dye binding assay [32].
Glomerular filtration rate (GFR). This was measured in
duplicate samples by either 3H-inulin clearance or creatinine
clearance techniques. These techniques give equivalent GFR
estimates in the IPK [33]. Control (N=6) and antiGBM anti-
body treated (N=6) IPK's in this laboratory had equivalent
GFR estimations with Clcreatinine and when simulta-
neously assessed [(Control:ml/min/g: Clcreatinine = 0.61 0.02
vs. Cl111 = 0.60 0.01) (antiGBM antibody treated: Clcreatinine
= 0.23 0.01 vs. Cl11 = 0.23 0.02)].
Renal vascular resistance (RVR). Perfusate pressure was
measured proximal to the arterial cannula with a calibrated
aneroid manometer. The cannula tip pressures were derived by
subtracting from the measured pressure the pressure drop
known to occur across a particular arterial cannula (of known
resistance at a given flow). Perfusate flow was measured by a
drop counter above the central reservoir Then, resistance =
cannula tip pressure (mm Hg)/perfusate flow (ml/min)
Creatinine (Cr) estimates. Creatinine was determined using a
colorimetric automated analyzer (Beckman Instruments, Pal
Alto, California, USA). Creatinine clearance was used in the
calculation of filtration fraction. This was equal to previously
described values (0.2 0.01) in all IPK preparations in the
current study.
Glomerular permselectivity studies: (A) Preparation of
radiolabelled dextrans. Radiolabelled neutral dextrans of a
wide molecular size distribution were prepared by oxidation of
commercial dextrans of known size (Tb, T40, T70, Pharmacia
Fine Chemicals, Uppsala, Sweden) by periodate and subse-
quent reduction by tritiated sodium borohydride (Amersham,
Sydney, Australia) according to the method of Chang et al [24].
Perfusate dextran concentrations were maintained at 100
mg/liter or less.
Radiolabelled dextran sulphate of a wide molecular size
distribution was prepared by hydrolyzing commercially avail-
able dextran sulphate (Pharmacia Fine Chemicals, mol wt
500,000) to an appropriate lower molecular weight fraction
using a modification [21] of the technique described by Chang et
al [25], where the duration of acid hydrolysis at 100°C was
reduced to 20 minutes. The tritium label was then introduced by
the same oxidation—reduction formula utilized for neutral
dextrans.
(B) Chromatographic procedures. Sephadex G100 (Pharma-
cia) was used with a 0.05 N solution of ammonium acetate as
buffer. Chromatographic columns [(1.6 cm ID x 100 cm) and
(1.8 ID x 120 cm)] (Pharmacia) were used. Eluted fractions
were collected with an automatic fractionator (LKB Wallac,
ULTRARAC 7000, Stockholm, Sweden). The columns were
calibrated using bovine serum albumin (Sigma, trypsinogen,
carbonic anhydrase, and lysozyme. Blue dextran (2 mg/ml) was
used to determine the void volume (Vo). The fractional volume
available to the solute (KAy) was calculated, and this related to
the molecular weight and Stokes Einstein radii of eluted frac-
tions using the methods described by Chang et al (27). The
specific activities of the tritiated dextrans were determined
using a liquid scintillation spectrometer (LKB Wallac,
ULTRABETA) with scintillation produced by mixing 1 ml of
aqueous sample with 5 ml of scintillation fluid.
(C) The origin of urinary protein in the IPK was further
studied in both normal and antiGBM antibody treated prepara-
tions. A F(ab) preparation of a rat antiFXlA antibody was
added to the perfusate 30 minutes prior to cessation of perfusion
and tissue fixed by immersion in liquid nitrogen. Eight micron
cryostat sections were then examined, after staining with a
fluorsceinated antisera to rat IgG (Sigma) for proximal tubule
epithelial staining (positive epithelial staining reflecting an in-
creased glomerular permeability to macromolecules [221).
Histological assessment
For immunofluorescence, tissue was taken after completion
of perfusion, snap—frozen in liquid nitrogen and stored at
—70°C. Two micron frozen sections were cut on a cryostat and
then stained with antisera to sheep globulin (IgG, Dakopatts,
Sweden); sheep C3 (Research Plus Inc., Bayonne, New Jersey,
USA); rat IgG (Sigma) and rat C3 (United States Biochemical
Corporation, Cleveland, Ohio). The sections were examined
under a Leitz Othlux II UV microscope (Leitz, Germany).
Antibodies
Normal sheep globulin (NSG). Normal sheep serum was
extensively absorbed against SD rat red blood cells (RBC's) and
plasma. A globulin fraction was obtained by precipitation with
saturated ammonium sulphate. The precipitate was resus-
pended in phosphate buffered saline (PBS) and passed through
a 0.22 ji filter.
Sheep-antirat GBM globulin (antiGBM antibody). Sheep
were repeatedly immunized with particulate SD GBM as pre-
viously described [34]. When a high titer of antiGBM antibody
was established, as determined by radioimmunoassay (RIA) the
sheep was sacrificed. The sera was absorbed and a globulin
fraction prepared as for NSG.
Quantitation of antibody binding. Globulin binding studies
were performed as previously described [35] by trace radiola-
belling the globulin (NSG or antiGBM-Ab with '31lodine and
'2tlodine, respectively) using the Chloramine-T technique [36].
Trace labelled globulin was added at the end of the IPK
equilibration period to a known volume of perfusate, and
perfusate was sampled after thorough mixing had occurred for
determination of its specific activity. At the desired time the
kidney was removed from the perfusion apparatus, trimmed of
capsule, excess connective tissue and fat and the renal cortex
dissected free. The cortex was then weighed before being
homogenized in a glass tube homogenizer. The homogenate was
repeatedly washed in 50 ml of PBS then spun at 500 x g for five
minutes. This was repeated until the supernatant was clear.
From the quantities of radioactivity in the final pellet (LKB
Wallac, 1280 Ultragamma) and the specific activities of the
perfusate, the quantity of globulin bound to the kidney was
determined and expressed as sg of globulin bound to each gram
of renal cortex (.tg/g). Specific antibody binding [kidney fixed
antibody (KFA)] was calculated as previously reported [35].
Experimental design
In all experiments the IPK was allowed to equilibrate for 10
minutes prior to the addition of antibodies, at to. The perfusions
continued for a maximum of 150 minutes, with protein excre-
tion, GFR, RVR and FRNS calculated for each 20 minute
interval to quantitate renal function. Permselectivity was as-
sessed from the 20 to 60 minute time points. Control (NSG)
perfusions contained concentrations of globulin equivalent to
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Fig. 1. Permselectivity in control IPK preparations. The negative
charge barrier was intact in the IPK, as illustrated by the significantly
lower fractional clearances of anionic dextran sulphate molecules.
the maximal antibody concentrations achieved (1 mg/mI). The
antibody binding (KFA) was assessed by studying the quantity
of specifically bound antibody at 120 minutes.
Statistical methods
Data is expressed as mean SCM. Significance was deter-
mined using the Student's t-test for the comparison of means
and by the analysis of variance [37].
Results
BAS Perfused controls (Table 1, Fig. 1)
Isolated rat kidneys, perfused with a buffered albumin solu-
tion with added normal sheep globulin (1 mg/ml) had stable
function for the 120 minutes of the study. Over this period the
protein excretion was (mean sCM) 0.223 0.044 mg/mm,
GFR (mean sCM) 0.63 0.08 ml/min/g and RVR (mean
sCM) 3.10 0.47mm Hg/mi/mm. IF was negative for sheep IgG
and rat C3. There was no proximal tubule epithelial staining for
rat globulin in control preparations perfused with rat antiFXlA
antibody.
Neutral dextran (N — 8) and Dextran sulphate (N = 6)
perfusions of BAS controls showed glomerular permselectivity
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Table 1. Control IPK function (N — 13)
Parameter SCM Time
(mm) 20 40 60 80 100
Protein excretion, 0.253 0.174 0.155 0.217 0.231 0.309
mg/mm 1 0.028
Glomerular filtration 0.68 0.67 0.63 0.60 0.62 0.57
rates, mi/min/g 0.08 ÷0.09 ÷0.08
Renal vascular 3.23 2.72 2.82 2.83 3.27 3.90
resistance, mm 0.20 ÷0.34
Hg/mimic
Perfusate flow, 29.5 31.2 31.5 29.9 28.9 28.2
mlmi'r' ÷1.0
Perfusion pressure, 95.3 84.9 88.8 84.6 94.5 110.0
mm Hg ÷1.6 ÷1.4
120
(C
C)
C
5)
C)
a)0
(-5
0)
C
>
a)
(1)
20 30 40
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Table 2. Effects of antibody alone on IPK function
AntiGBM
antibody
KFA N
Parameter/time
(mm) SEM 20 40 60 80 100 120
385 ig/g 9 Protein excretion,
mg/mm
GFR, ml/min/g
RVR, mm Hg/mI/mm
Perfusate flow,
ml min'
Perfusion pressure,
mm Hg
0.487
0.49
3.75
26.5
99.4
1.058
0.40
4.43
24.4
108.1
1.214
0.34
4.20
22.1
92.8
1.668
0.27
4.94
20.7
102.3
2.502
0.31
5.26
19.7
103.6
5.126
0.23
6.41
18.1
116.0
183 jg/g 6 Protein excretion,
mg/mm
GRF, ml/min/g
RVR, mm Hg/mi min1
Perfusate flow, ml min'
Perfusion pressure,
mm Hg
0.337
0.51
4.04
24.9
100.6
0.237
0.47
3.92
25.9
101.5
0.248
0.42
4.91
22.1
108.5
0.326
0.41
5.12
21.7
111.1
0.316
0.38
5.06
21.9
110.8
0.374
0.28
5.25
21.0
110.3
89 g/g 4 Protein excretion,
mg/mm
0.200 0.200 0.213
106
0.209 0.236 0.274
Fig. 2. AntiGBM antibody binding in the JFK. Immunofluorescence
showed linear deposition of IgG in the isolated perfused kidney after
administration of antiGBM antibody.
Fig. 3. Antibody effects on giomerular perselectivity: neutral dextran
clearances. Administration of antiGBM antibody (0) decreased the
sieving coefficient for neutral dextrans compared with control values(.)
Effects of antiGBM antibody (Table 2, Figs. 3, 4)
AntiGBM-Ab binding (KFA 385 g/g) produced a marked
increase in protein excretion rate (overall mean SEM; 2.009
0.681 mg/mm, P < 0.01). Antibody administration also pro-
duced hemodynamic changes [at KFA 385 g/g, an increased
RYR (4.83 0.52 mm Hg/ml/min, P < 0.01), a decreased GFR
(0.34 0.04 mllminlg, P < 0.01), at KFA 183 g/g, an increased
RVR (4.72 0.48 mm Hg/mi min1, P < 0.01) and a decreased
GFR (0.41 0.05 mllmin/g, P < 0.01)]. There were equivalent
hemodynamic alterations at both these antibody binding levels,
1.0•
0.5
G)0
5)00
0)0
>
a)
U)
30
Stokes Einstein radius, A
characteristics substantially similar to those reported for the SD
and Munich—Wistar rats in vivo, as we have reported elsewhere
[21]. In particular, the negative charge barrier on the glomerular
filter was intact (such as, fractional clearance of neutral dextran
36A radius = 0.10 0.01, cf. fractional clearance of negatively
charged dextran sulphate 0.01 0.00, P < 0.01), (Fig. 1).
Globulin/antibody binding studies (Fig. 2)
Antibodies bound to the perfused kidney in a dose related
fashion. AntiGBM-Ab was shown to localize to the GBM on IF,
with no significant staining of the vascular endothelium or renal
tubular basement membrane. There was no glomerular deposi-
tion of rat C3 on IF.
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Fig. 4. Antibody effects on glomerular perselectivity: dextran sulphate
clearances. Administration of antiOfiM antibody (0) increased the
seiving coefficient for negatively charged dextran sulphate moieties
compared with control values (•), indicating a loss of the negative
charge barrier normally present on the glomerular filter.
despite normal protein excretion rates at the lower dose. These
data demonstrate that hemodynamie changes are not contribut-
ing significantly to antibody induced proteinuria and suggest
that there are different KFA thresholds for the permelectivity
and hemodynamic changes induced by antiGBM antibody [381.
The addition of antiGBM-Ab was associated with a signifi-
cant decrease in permeability to all neutral dextran molecules
over 21 A Stokes—Einstein radius, reflected by the fall in their
fractional dextran clearance/sieving coefficient (Fig. 4).
AntiGBM antibody produced a significant increase in perme-
ability to all sizes of negatively—charged dextran sulphate
moieties, (that is, increased fractional dextran clearance/sieving
coefficient) indicating that antiGBM antibody administration
resulted in a loss of the normal net negative charge barrier of the
glomerular filter (Fig. 4). The 385 tg/g KFA antiGBM antibody
perfusions had extensive proximal convoluted tubule epithelial
rat IgG staining when an F(ab) preparation of rat antiFXlA
antibody was added to the perfusate reservoir, confirming that
antiGBM antibody produced an increase in glomerular protein
permeability. Antibody binding at lower KFA levels was not
associated with significant changes in the rate of protein excre-
tion and there was no antiFXlA staining of proximal convo-
luted tubule epithelium in these preparations.
Discussion
The isolated rat kidney perfused with an oxygenated,
cell—free, oncotically—active solution is an accepted model for a
variety of physiological, metabolic and pharmacological studies
of renal function [39, 401. Although only rarely used for
nephroimmunological studies [22, 42], the facility with which
perfusate composition may be altered provides a unique oppor-
tunity to directly study the effects of the sequential addition of
factors which may play a role in immune renal injury. In the
current study control values for GFR, RYR, and protein
excretion are comparable to those previously reported for the
technique [39, 401.
The landmark study of Cochrane et al established the role of
complement and neutrophils in producing injury following
antiGBM antibody deposition [10]. Subsequently many authors
have confirmed the importance of the complement/neutrophil
interaction in antiGBM GN, which is regarded as a neutro-
phil—dependent model of renal injury [4, 5, 9]. However several
observations suggest that additional, neutrophil—independent
mechanisms of glomerular injury also exist [15]. Even in the
initial study of Cochrane et al, it was observed that large doses
of antiGI3M antibody caused an acute increase in urinary
protein excretion which could not be prevented by neutrophil or
complement depletion [10]. In the interpretation of these find-
ings it was suggested that alternate mediator systems (such as
kinins and fibrin) were activated by high levels of antiGBM
binding, or that despite relative complement and polymorph
depletion, high levels of antibody binding could induce suffi-
cient complement fixation and polymorph influx to produce
injury. The current experiments utilizing the IPK confirm that
antiGBM antibody administration in appropriate doses can
produce an increased glomerular protein excretion in the rat
kidney without the involvement of any circulating soluble
inflammatory mediators or inflammatory cells. These IPK stud-
ies clearly demonstrate the potential for acute renal injury
secondary to glomerular antibody deposition. However, in
vivo, glomerular antibody deposition initiates local complement
activation with consequent leucocyte accumulation. In vivo
each component of this 'triad' of inflammatory mediators (that
is, antibody deposition, complement activation, and leucocyte
infiltration) undoubtedly contributes to acute glomerular injury.
The relative contribution of each of these mediators varies in
relationship to species [10, 16—20], the site of antigen—antibody
interaction [43] and the quantity of deposited immunoglobulin.
Much information has accrued to suggest that albumin is
normally prevented from crossing the glomerular filtration
barrier largely by virtue of the net negative charge on the
glomerular filter [22—26]. Prior to investigating the mechanism
of increased protein excretion with antiGBM antibody binding,
the normal permselectivity characteristics of control IPK prep-
arations were determined. These studies demonstrated that
glomerular permselectivity for both neutral and negatively
charged dextrans of various molecular size was essentially
similar to that of the SD rat in vivo [21]. Our control IPK system
showed an increased protein excretion, when compared with
the rat in vivo, of similar magnitude to that reported by other
investigators [22, 33, 39—42]. It has been suggested that this
increased albumin excretion is of a non-glomerular origin [221.
However, micropuncture studies in the IPK show an increased
early proximal tubule (EPT) albumin concentration compared
with in vivo [42], indicating that the IPK has either an increased
seiving coefficient for albumin or a failure of EPT albumin
reabsorption. An increased seiving coefficient for albumin in the
IPK cannot be on the basis of an abnormality of the size or
charge selectivity of the glomerular filter, as fractional dextran
clearances are essentially similar to in vivo values [21]. It is
likely that the markedly altered hemodynamics of the IPK,
together with alterations in the secondary structure of albumin
in the IPK perfusate, results in an increased albumin sciving
coefficient despite normal size and charge selectivity (that is,
normal fractional dextran clearances) [21, 41].
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The addition of antiGBM antibody produced a decrease in
permeability to all but the smallest neutral dextran molecules
(<21A), with a marked increase in permeability to all dextran
sulphate moieties. These two results demonstrate that the
normal negative charge barrier of the glomerular filter was
destroyed by the addition of antiGBM antibody. The loss of the
charge barrier in association with the development of protein-
uria suggests that the two are causally linked. The changes in
gloinerular permselectivity in the IPK with antiGBM antibody
administration alone are similar to those reported by Chang et al
in an in vivo model of the autologous phase of antiGBM
glomerulonephritis involving antibody, complement, and cellu-
lar infiltration [44, 451. However, in in vivo studies involving the
simultaneous activation of multiple cellular and humoral medi-
ators at the site of injury, the individual contributions to injury
cannot be discerned. The current studies demonstrate that loss
of the negative charge barrier with an increased glomerular
protein permeability can be induced by antibody deposition
alone.
The mechanism of the antiGBM antibody induced loss of the
negative charge barrier and the increased protein excretion rate
seen in the current study was uncertain. Antibody may bind to
specific basement membrane antigenic determinants, which are
important in the maintenance of normal permselectivity, and by
altering these may directly lead to abnormal membrane perme-
ability. Alternatively, antibody binding may stimulate the re-
lease of inflammatory mediators from intrinsic renal parenchy-
mal cells, and these substances might then alter membrane
permeability to albumin. The potential significance of the re-
lease of such inflammatory mediators by intrinsic renal cells has
recently been reinforced with the demonstration by Pirotsky et
al, of the generation and release of such a mediator (that is,
platelet activating factor) from renal parenchymal cells [461.
Summary
These studies in an IPK system have demonstrated the ability
of antiGBM antibody to produce injury in the rat kidney in the
absence of all other circulating inflammatory mediators. The
increased protein excretion which occurred with antibody bind-
ing to the GBM was associated with loss of the functional
negative charge barrier on the GBM. Such inflammatory
cell—independent immune renal injury may potentially be im-
portant in experimental glomerulonephritis and may help ex-
plain the inflammatory cell independent injury seen in many
forms of human glomerulonephritis.
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